Point of Care Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase (OTC, Prescription), Sample (Blood, Urine), End User (Pharmacy, Hospital, Homecare) & Region - Global Forecast to 2027
The global point of care diagnostics market in terms of revenue was estimated to be worth $45.4 billion in 2022 and is poised to reach $75.5 billion by 2027, growing at a CAGR of 10.7% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. In the latest edition of the report, new product and sample segments have been added. The updated report will have a segment dedicated to providing a detailed understanding of different types of point of care products and samples. The growth of this market can be attributed to the high prevalence of respiratory diseases such as influenza, cardiac diseases, and infectious diseases (where point of care tests can greatly improve the management of these diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse). Furthermore, with the increasing availability of point of care testing products via online platforms, supportive government policies, and an increase in the number of CLIA-waived point of care tests, healthcare decentralisation and greater investments and funding for product development are expected to accelerate the growth of the market in the coming years.
However, factors such as pricing pressure owing to reimbursement cuts and budget constraints are expected to hamper the growth of the market during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
Point of Care Diagnostics Market Dynamics
Driver: increasing prevalence of infectious diseases
It is possible to diagnose and treat these extremely contagious diseases quickly thanks to point-of-care tests with high sensitivity and specificity. The need for point-of-care diagnostics for the quick detection of infectious diseases is probably going to increase as infectious diseases like HIV, hepatitis, influenza, and tuberculosis become more common. The key data on the main infectious diseases affecting developing nations is provided below:
- According to the National Aids Control Organization (NACO), in 2021, approximately 2.40 million people in India were infected with HIV. Of the total HIV-infected population, 45% were women, and 2% were children under the age of 12.
- According to the WHO Global TB Report 2021, of the 1.7 billion global population infected with TB, around 587 million people with TB reside in Southeast Asia (SEA).
Opportunity: Point of care tests with multiplexing capabilities.
A single point-of-care device that can run multiple analytes is being developed by businesses. Multiplexing, which these devices are capable of, is the simultaneous measurement of multiple analytes on a single cartridge. Comparing widely used singleplex tests to multiplex point-of-care tests, multiplex point-of-care tests have a number of advantages, including higher throughput, higher output per sample, and increased efficiency at lower costs. These advantages will support the advancement of personalised medicine as well as the development of more accurate and thorough diagnostics. One example of a multiplexed device is Alere's Triage 8 Panel for Drugs of Abuse, an immunoassay that can identify the main metabolites of drugs of abuse and yield results in just 10 minutes. A number of market players will experience new opportunities for growth as a result of the commercialization of such high-tech and affordable multiplex point-of-care tests.
Restraint: pricing pressure owing to reimbursement cuts and budget constraints.
The growth of the global market has been impacted by the pricing pressure brought on by reimbursement reductions and insufficient budgets. The Diagnosis Related Group (DRG) system in France makes reimbursement a negligible factor by bundling all patient care costs into a single prospective payment. In the nation, the payment for diabetes technologies in outpatient settings is based on a tariff system.
Additionally, the number of healthcare products that qualify for reimbursement has reportedly decreased, which makes it difficult for manufacturers to maintain prices as the competition heats up. The future expansion of the global market is anticipated to be significantly hampered by this factor.
The Glucose Monitoring Product segment accounted for a sizable portion of the global point of care diagnostics industry by product type.
The demand for glucose monitoring products is anticipated to increase during the forecast period as a result of the rising prevalence of diabetes and increased patient awareness of the market's availability of point-of-care testing. The number of people with diabetes is expected to rise from 425 million in 2017 to 642 million by 2040, according to the IDF Diabetes Atlas.
In the upcoming years, it is anticipated that the number of businesses concentrating on the development of cutting-edge self-monitoring glucose meters, such as Medtronic's Guardian Sensor 3—a diagnostic chip that automatically monitors health—and Roche's Accu-Chek Blood Glucose Monitoring System with wireless connectivity and app support—will promote the growth potential of this segment.
The lateral flow assays segment, by platform type, accounted for the largest share of the global point of care diagnostics industry.
The rapid uptake of LFA testing products in home care settings, the increased focus of market participants on creating cutting-edge LFA-based point of care devices, and growing knowledge of the benefits of lateral flow assay-based point of care tests as a replacement for time-consuming laboratory procedures and the lower cost associated with this procedure over traditional laboratory procedures are anticipated to accelerate the growth of the lateral flow assays segment of the point of care diagnostics market over the coming years.
The home care and self-testing segments are expected to have the highest CAGR of the point of care diagnostics industry in terms of end users.
During the forecast period, the segment for home care and self-testing is anticipated to have the highest CAGR. Patients and emergency responders who use monitoring devices in residential settings make up the segment's end users. In this segment, equipment like blood glucose meters, blood pressure monitors, HIV test kits, pregnancy test kits, and test kits for respiratory infections are frequently used. One of the main reasons for the rise in popularity of home testing kits is their simplicity of use. Other important reasons include their lower cost and wider availability. In the near future, the home care and self-testing segments will continue to grow as a result of numerous market players and government agencies forming joint ventures, partnerships, and collaborations to create innovative and affordable products suitable for home care requirements.
In July 2022, the Clinton Health Access Initiative (CHAI), MedAccess, and Wondfo Biotech Company entered into a strategic partnership with the aim of providing the HIV self-test for USD 1 to the public sector in low- and middle-income countries. This initiative will increase the accessibility of affordable HIV self-testing globally.
To know about the assumptions considered for the study, download the pdf brochure
The Asia Pacific market is expected to grow at the highest CAGR of the point of care diagnostics industry during the forecast period.
Latin America, the Middle East, North America, Europe, and Africa are the sub-regions of the point of care diagnostics market. The majority of the market is in North America. It is anticipated that the North American market will expand as a result of the rising prevalence of lifestyle diseases, government initiatives to encourage the widespread use of point-of-care diagnostics, and the significant presence of key players in the region..
A growing patient population, an increase in hospitals and clinical diagnostics laboratories, the emergence of new rapid test kit manufacturers, rising healthcare costs, and expanding player collaborations are all contributing factors that will cause Asia Pacific to experience the highest growth during the forecast period.
Prominent players in the point of care diagnostics market are Abbott Laboratories (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (a Werfen Company) (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux S.A. (France).
Abbott:
Abbott Laboratories is the leading player in the market. The strong focus on strengthening its brand presence and continuous investments in R&D to introduce novel products and improve its existing product line and processes are expected to help Abbott witness significant growth in the point-of-care diagnostics market during the forecast period. To expand its global diagnostics presence and leadership in the point-of-care diagnostics market, the company acquired Alere, Inc. in October 2017, gaining access to new channels and Alere's high-quality products.
Scope of the Point of Care Diagnostics Industry
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$45.4 billion |
|
Projected Revenue by 2027 |
$75.5 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 10.7% |
|
Market Driver |
Increasing prevalence of infectious diseases |
|
Market Opportunity |
POC tests with multiplexing capabilities |
This research report categorizes point of care diagnostics market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- COVID-19 test products
-
Glucose Monitoring Products
- Strips
- Meters
- Lancets & Lancing Devices
-
Cardiometabolic Monitoring Products
- Point-of-care and rapid diagnostics Products
- Blood Gas/Electrolyte Testing Products
- HbA1c Testing Products
-
Infectious Disease Testing Products
- Influenza Testing Products
- HIV Testing Products
- Hepatitis C Testing Products
- Influenza Testing Products
-
Sexually Transmitted Disease Testing Products
- Syphilis Testing Products
- Human Papillomavirus (HPV) Testing Products
- Chlamydia Trachomatis Testing Products
- Herpes simplex virus (HSV) Testing Products
- Healthcare-associated Infection Testing Products
- Respiratory Infection Testing Products
- Tuberculosis (TB) Testing Products
- Clostridium Difficile Infection (CDI) Testing Products
- Tropical Disease Testing Products
- Other Infectious Disease Testing Products
-
Coagulation Monitoring Products
- PT/INR Testing
- ACT/APTT
-
Pregnancy & Fertility Testing Products
- Pregnancy Testing Products
- Fertility Testing Products
- Tumor/Cancer Marker Testing Products
- Urinalysis Testing Products
- Cholesterol Testing Products
- Hematology Testing Products
- Thyroid Stimulating Hormone (TSH) Testing Products
- Drugs-of-abuse Testing Products
- Fecal Occult Testing Products
- Other POC Products
By Platform
- Lateral Flow Assays
- Dipsticks
- Microfluidics
-
Molecular Diagnostics
- Polymerase Chain Reaction(PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Other Molecular Diagnostic Technologies
- Immunoassays
By Mode of Purchase
- Prescription-based Products
- OTC Products
By Sample
- Blood
- Urine
- Nasal and Oropharyngeal Swabs
- Other Samples
By End User
- Clinical Laboratories
- Ambulatory Care Facilities and Physician Offices
- Pharmacies, retail clinics, & E-comm. Platforms
- Hospitals, Critical Care Centers, Urgent care centers
- Home Care & Self Testing
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
-
Latin America
- Brazil
- Mexico
- RoLATAM
- Middle East & Africa
Recent Developments of the Point of Care Diagnostics Industry
- In May 2022, QuantuMDx announced the launch of its new respiratory panel test; Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay.
- In March 2022, Boditech Med entered in strategic partnership with Novo Integrated Sciences, Inc. with an aim to expand its biomarker based rapid testing product line across North America
- In January 2022, Roche launched its Cobas Pulse System in select countries accepting the CE Mark. This is Roche Diagnostics’ newest generation of connected point-of-care solutions for professional blood glucose management.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global point of care diagnostics market?
The global point of care diagnostics market boasts a total revenue value of $75.5 billion by 2027.
What is the estimated growth rate (CAGR) of the global point of care diagnostics market?
The global point of care diagnostics market has an estimated compound annual growth rate (CAGR) of 10.7% and a revenue size in the region of $45.4 billion in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 48)
1.1 STUDY OBJECTIVES
1.2 POINT OF CARE DIAGNOSTICS INDUSTRY DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 INCLUSIONS AND EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 53)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 POINT OF CARE DIAGNOSTICS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
2.4.1 RESEARCH ASSUMPTIONS
2.4.2 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 63)
FIGURE 7 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 8 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY, BY PLATFORM, 2022 VS. 2027 (USD MILLION)
FIGURE 9 GLOBAL MARKET, BY MODE OF PURCHASE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY
4 PREMIUM INSIGHTS (Page No. - 67)
4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
FIGURE 12 RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET
4.2 GLOBAL MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GLUCOSE MONITORING PRODUCTS SEGMENT WILL DOMINATE MARKET IN 2027
4.3 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY SHARE, BY MODE OF PURCHASE (2022)
FIGURE 14 OTC TESTING PRODUCTS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE IN 2022
4.4 GLOBAL MARKET SHARE, BY PLATFORM, 2022 VS. 2027
FIGURE 15 LATERAL FLOW ASSAYS WILL CONTINUE TO DOMINATE MARKET IN 2027
4.5 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 71)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 High prevalence of infectious diseases
FIGURE 18 HIV INFECTION, BY REGION, 2021
5.2.1.2 Increasing incidence of target conditions
5.2.1.3 Supportive government policies
5.2.1.4 Dearth of skilled laboratory technicians
5.2.1.5 Rising number of CLIA-waived POC tests
TABLE 1 RECENT WAIVERS FOR PRODUCTS
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints
5.2.2.2 Stringent regulatory policies
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Healthcare decentralization
5.2.3.3 Increasing provider awareness about novel technologies
5.2.3.4 POC tests with multiplexing capabilities
5.2.3.5 Growing investments and funding for product development
5.2.4 CHALLENGES
5.2.4.1 Lack of alignment with definitive central lab methods
5.2.4.2 Inadequate adoption of POC devices in professional settings
5.2.4.3 Reluctance to change existing diagnostic practices
5.2.4.4 Premium pricing of novel platforms
5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS
5.3.1 SEPSIS BIOMARKERS
5.3.2 STROKE/CARDIAC MARKERS
5.3.3 THYROID TESTING
5.3.4 DNA TESTING
5.3.5 ENDOCRINE TESTING
5.3.6 RESPIRATORY DIAGNOSTICS
5.4 REGULATORY LANDSCAPE
TABLE 2 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
5.4.1 KEY REGULATORY GUIDELINES
5.4.1.1 US
FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.2 Canada
FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.3 Europe
FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.4 Japan
FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.5 China
TABLE 3 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.1.6 India
FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.4.1.7 Brazil
FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.5 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 26 SUPPLY CHAIN ANALYSIS
5.7 PRICING TREND ANALYSIS
TABLE 4 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2021 (USD)
TABLE 5 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2021 (USD)
TABLE 6 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2021 (USD)
5.8 PORTER’S FIVE FORCES
5.8.1 OVERVIEW
TABLE 7 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.2 BARGAINING POWER OF BUYERS
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 THREAT OF NEW ENTRANTS
5.8.5 THREAT OF SUBSTITUTES
5.8.6 INTENSITY OF COMPETITIVE RIVALRY
5.9 PATENT ANALYSIS
FIGURE 27 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012–NOVEMBER 2022)
FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012–NOVEMBER 2022)
FIGURE 29 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS)
5.10 KEY CONFERENCES AND EVENTS
TABLE 8 GLOBAL MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS, 2021–2023
5.11 CASE STUDY
5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I
TABLE 9 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS
FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)
5.13 KEY BUYING CRITERIA
TABLE 11 KEY BUYING CRITERIA FOR PRODUCTS
6 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 98)
6.1 INTRODUCTION
TABLE 12 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 GLUCOSE MONITORING PRODUCTS
TABLE 13 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 14 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 15 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 16 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 17 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 18 GLOBAL MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.2.1 STRIPS
6.2.1.1 Strips make blood glucose testing easy and hassle-free
TABLE 19 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.2 METERS
6.2.2.1 Extremely helpful in monitoring blood glucose levels and adjusting therapeutic regimens
TABLE 20 GLUCOSE MONITORING METERS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.3 LANCETS AND LANCING DEVICES
6.2.3.1 Lancets and lancing devices segment to register lower growth in glucose monitoring products market
TABLE 21 GLUCOSE MONITORING LANCETS AND LANCING DEVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 COVID-19 TESTING PRODUCTS
6.3.1 COVID-19 PANDEMIC ACCELERATED DEMAND FOR POC/RAPID DIAGNOSTIC PRODUCTS
TABLE 22 MARKET FOR COVID-19 TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 23 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 24 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 25 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 26 GLOBAL MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.4 CARDIOMETABOLIC MONITORING PRODUCTS
TABLE 27 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 28 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 29 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 30 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 31 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 32 GLOBAL MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.4.1 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
6.4.1.1 Technological advancements in blood gas/electrolyte products to drive market
TABLE 33 MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.4.2 CARDIAC MARKER TESTING PRODUCTS
6.4.2.1 Rising prevalence of heart diseases and development of new POC test to support market growth
TABLE 34 GLOBAL MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.4.3 HBA1C TESTING PRODUCTS
6.4.3.1 Government initiatives promoting regular use of HbA1c testing
TABLE 35 GLOBAL MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5 INFECTIOUS DISEASE TESTING PRODUCTS
TABLE 36 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 38 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 39 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 40 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 41 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.1 HIV TESTING PRODUCTS
6.5.1.1 Rising prevalence of HIV to drive market
TABLE 42 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 43 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 44 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 45 GLOBAL MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.2 RESPIRATORY INFECTION TESTING PRODUCTS
6.5.2.1 POCT products for diagnosis of respiratory infections offer lower sensitivity
TABLE 46 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 47 GLOBAL MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 48 GLOBAL MARKET FOR RESPIRATORY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 49 GLOBAL MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.3 HEPATITIS C TESTING PRODUCTS
6.5.3.1 Central and East Asia among highly affected regions by hepatitis C
TABLE 50 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 51 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 52 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 53 GLOBAL MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
6.5.4.1 Rising prevalence of HAIs to drive market
TABLE 54 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 55 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 56 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 57 GLOBAL MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.5 INFLUENZA TESTING PRODUCTS
6.5.5.1 Rising influenza prevalence to drive demand for influenza testing products
TABLE 58 MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 59 GLOBAL MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 60 GLOBAL MARKET FOR INFLUENZA TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 61 GLOBAL MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.6 TROPICAL DISEASE TESTING PRODUCTS
6.5.6.1 Increasing government funding for use of POC in tropical disease testing to support market growth
TABLE 62 GLOBAL MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 63 GLOBAL MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 64 GLOBAL MARKET FOR TROPICAL DISEASES PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 65 GLOBAL MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
TABLE 66 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 68 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 69 GLOBAL MARKET FOR STD TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 70 GLBOAL MARKET FOR STD TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.7.1 Syphilis testing products
6.5.7.1.1 Introduction of rapid tests for syphilis to support market growth
TABLE 71 MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.7.2 Human papillomavirus (HPV) testing products
6.5.7.2.1 Technological advancements to aid market growth
TABLE 72 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.7.3 Chlamydia trachomatis testing products
6.5.7.3.1 Growing incidence of chlamydia and rising awareness among patients to drive market
TABLE 73 GLOBAL MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.7.4 Herpes simplex virus (HSV) testing products
6.5.7.4.1 Increasing incidence of HSV to boost adoption of rapid tests
TABLE 74 GLOBAL MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.8 TUBERCULOSIS (TB) TESTING PRODUCTS
6.5.8.1 Rising prevalence of TB and initiatives by governments to propel demand for rapid TB tests
TABLE 75 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 76 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 77 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 78 GLOBAL MARKET FOR TB TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.9 CLOSTRIDIUM DIFFICILE INFECTION (CDI) TESTING PRODUCTS
6.5.9.1 Increasing cases of CDI infections among hospitalized patients to support market growth
TABLE 79 GLOBAL MARKET FOR CDI TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 80 GLOBAL MARKET FOR CDI TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 81 MARKET FOR CDI TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 82 GLOBAL MARKET FOR CDI TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.5.10 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
TABLE 83 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 84 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 85 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 86 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.6 COAGULATION MONITORING PRODUCTS
TABLE 87 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 89 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 90 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 91 MARKET FOR COAGULATION MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 92 GLOBAL MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.6.1 PT/INR TESTING PRODUCTS
6.6.1.1 Most commonly used coagulation monitoring method
TABLE 93 GLOBAL MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.6.2 ACT/APTT TESTING PRODUCTS
6.6.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth
TABLE 94 GLOBAL MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.7 PREGNANCY AND FERTILITY TESTING PRODUCTS
TABLE 95 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 97 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 98 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 99 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 100 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.7.1 PREGNANCY TESTING PRODUCTS
6.7.1.1 Rising inclination toward home testing to support market growth
TABLE 101 GLOBAL MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.7.2 FERTILITY TESTING PRODUCTS
6.7.2.1 Increasing awareness of fertility testing to drive market
TABLE 102 GLOBAL MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.8 TUMOR/CANCER MARKER TESTING PRODUCTS
6.8.1 INCREASING PREVALENCE OF CANCER TO BOOST DEMAND FOR RAPID TESTING
TABLE 103 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 104 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 105 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 106 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 107 GLOBAL MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.9 URINALYSIS TESTING PRODUCTS
6.9.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS TO DRIVE MARKET
TABLE 108 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 109 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 110 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 111 MARKET FOR URINALYSIS TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 112 GLOBAL MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.10 CHOLESTEROL TESTING PRODUCTS
6.10.1 RISING OBESITY LEVELS TO DRIVE ADOPTION OF CHOLESTEROL TESTING PRODUCTS
TABLE 113 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 114 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 115 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 116 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 117 GLOBAL MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.11 HEMATOLOGY TESTING PRODUCTS
6.11.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS TO IMPEDE MARKET GROWTH
TABLE 118 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 119 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 120 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 121 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 122 GLOBAL MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.12 DRUGS-OF-ABUSE TESTING PRODUCTS
6.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO BOOST DEMAND FOR TESTING
TABLE 123 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 124 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 125 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 126 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 127 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.13 FECAL OCCULT TESTING PRODUCTS
6.13.1 LACK OF PROPER TRAINING FOR FECAL OCCULT TESTING TO HAMPER MARKET GROWTH
TABLE 128 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 129 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 130 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 131 MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 132 GLOBAL MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.14 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS
6.14.1 RISING CASES OF THYROID TO BOOST ADOPTION OF RAPID TESTS
TABLE 133 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 134 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 135 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 136 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 137 GLOBAL MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
6.15 OTHER PRODUCTS
TABLE 138 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 139 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 140 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 141 OTHER GLOBAL MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
TABLE 142 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
7 POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (Page No. - 177)
7.1 INTRODUCTION
TABLE 143 GLOBAL POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
7.2 LATERAL FLOW ASSAYS
7.2.1 INCREASING ADOPTION OF LFA TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET
TABLE 144 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY FOR LATERAL FLOW ASSAYS, BY REGION, 2020–2027 (USD MILLION)
7.3 IMMUNOASSAYS
7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH
TABLE 145 GLOBAL MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION)
7.4 MICROFLUIDICS
7.4.1 EMERGING PLATFORM IN POC DIAGNOSTICS MARKET
TABLE 146 GLOBAL MARKET FOR MICROFLUIDICS, BY REGION, 2020–2027 (USD MILLION)
7.5 DIPSTICKS
7.5.1 DIPSTICKS HELP IN ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS
TABLE 147 GLOBAL MARKET FOR DIPSTICKS, BY REGION, 2020–2027 (USD MILLION)
7.6 MOLECULAR DIAGNOSTICS
TABLE 148 GLOBAL POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 GLOBAL MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
7.6.1 RT-PCR
7.6.1.1 COVID-19 testing boosted demand for RT-PCR technology
TABLE 150 GLOBAL MARKET FOR RT-PCR, BY REGION, 2020–2027 (USD MILLION)
7.6.2 INAAT
7.6.2.1 Cost benefits of INAAT to drive adoption
TABLE 151 GLOBAL MARKET FOR INAAT, BY REGION, 2020–2027 (USD MILLION)
7.6.3 OTHER TECHNOLOGIES
TABLE 152 GLOBAL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
8 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (Page No. - 187)
8.1 INTRODUCTION
TABLE 153 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
8.2 OTC TESTING PRODUCTS
8.2.1 RISING FOCUS ON HOME CARE TO BOOST DEMAND FOR OTC TESTING PRODUCTS
TABLE 154 OTC POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
8.3 PRESCRIPTION-BASED TESTING PRODUCTS
8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT TO DRIVE MARKET
TABLE 155 PRESCRIPTION-BASED POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
9 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE (Page No. - 191)
9.1 INTRODUCTION
TABLE 156 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY, BY SAMPLE, 2020–2027 (USD MILLION)
9.2 BLOOD
9.2.1 RISING APPLICATION OF BLOOD SAMPLES IN DETECTION OF VARIOUS DISEASES TO DRIVE GROWTH
TABLE 157 GLOBAL MARKET FOR BLOOD SAMPLES, BY REGION, 2020–2027 (USD MILLION)
9.3 URINE
9.3.1 GROWING PREVALENCE OF KIDNEY DISORDERS TO BOOST MARKET GROWTH
TABLE 158 GLOBAL POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2020–2027 (USD MILLION)
9.4 NASAL AND OROPHARYNGEAL SWABS
9.4.1 INCREASING PREVALENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET GROWTH
TABLE 159 GLOBAL MARKET FOR NASAL AND OROPHARYNGEAL SWABS, BY REGION, 2020–2027 (USD MILLION)
9.5 OTHER SAMPLES
TABLE 160 GLOBAL MARKET FOR OTHER SAMPLES, BY REGION, 2020–2027 (USD MILLION)
10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER (Page No. - 196)
10.1 INTRODUCTION
TABLE 161 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
10.2 CLINICAL LABORATORIES
10.2.1 IMPROVEMENTS IN CLINICAL DIAGNOSTICS AND TESTING TECHNOLOGIES TO DRIVE MARKET
TABLE 162 GLOBAL MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES
10.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE—MAJOR FACTORS DRIVING MARKET GROWTH
TABLE 163 GLOBAL MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2020–2027 (USD MILLION)
10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS
10.4.1 CONVENIENCE AND EASE OF EXPERT ACCESS TO DRIVE MARKET
TABLE 164 GLOBAL POINT OF CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2020–2027 (USD MILLION)
10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
10.5.1 HOSPITALS LARGEST END USERS OF POC DIAGNOSTICS
TABLE 165 GLOBAL MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2020–2027 (USD MILLION)
10.6 HOME CARE AND SELF-TESTING
10.6.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE TO DRIVE MARKET
TABLE 166 GLOBAL MARKET FOR HOME CARE AND SELF-TESTING, BY REGION, 2020–2027 (USD MILLION)
10.7 OTHER END USERS
TABLE 167 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION (Page No. - 203)
11.1 INTRODUCTION
TABLE 168 GLOBAL POINT OF CARE DIAGNOSTICS INDUSTRY, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
TABLE 169 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 170 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 171 NORTH AMERICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 172 NORTH AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 173 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 NORTH AMERICA: POINT OF CARE DIAGNOSTICS INDUSTRY FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 175 NORTH AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 176 NORTH AMERICA: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 177 NORTH AMERICA: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 178 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 179 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 US dominates North American POC diagnostics market
TABLE 180 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 181 US: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 182 US: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 US: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 US: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Rising government initiatives to support growth of POC diagnostics market in Canada
TABLE 185 CANADA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 186 CANADA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 CANADA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 CANADA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189 CANADA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 190 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 191 EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 192 EUROPE: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 193 EUROPE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 194 EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 EUROPE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 196 EUROPE: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 EUROPE: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 198 EUROPE: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 199 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 200 EUROPE: POINT OF CARE DIAGNOSTICS INDUSTRY, BY SAMPLE, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Largest market for POC diagnostics in Europe
TABLE 201 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 202 GERMANY: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 GERMANY: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 204 GERMANY: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 205 GERMANY: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Growing public-private collaborations for product development to drive market
TABLE 206 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 207 FRANCE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 FRANCE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209 FRANCE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 210 FRANCE: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.3.3 UK
11.3.3.1 Benefits of POC diagnostics to support market growth
TABLE 211 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 212 UK: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 UK: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 214 UK: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 215 UK: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Rising prevalence of chronic diseases to drive demand for POC diagnostics
TABLE 216 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 217 ITALY: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 ITALY: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219 ITALY: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220 ITALY: POINT OF CARE DIAGNOSTICS INDUSTRY FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Rising geriatric population to support market growth
TABLE 221 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 222 SPAIN: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 223 SPAIN: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 224 SPAIN: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 225 SPAIN: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 226 REST OF EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 227 REST OF EUROPE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 REST OF EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 229 REST OF EUROPE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 230 REST OF EUROPE: POINT OF CARE DIAGNOSTICS INDUSTRY FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 33 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
TABLE 231 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 232 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 233 ASIA PACIFIC: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234 ASIA PACIFIC: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 235 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 236 ASIA PACIFIC: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 237 ASIA PACIFIC: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 ASIA PACIFIC: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 239 ASIA PACIFIC: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 240 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 241 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS INDUSTRY, BY SAMPLE, 2020–2027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Japan to dominate Asia Pacific POC diagnostics market during forecast period
TABLE 242 JAPAN: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 243 JAPAN: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244 JAPAN: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 245 JAPAN: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 246 JAPAN: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Rising investments by market players and government to drive market
TABLE 247 CHINA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 248 CHINA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 CHINA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 250 CHINA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 251 CHINA: POINT OF CARE DIAGNOSTICS INDUSTRY FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 High burden of chronic diseases to support market growth
TABLE 252 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 253 INDIA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 254 INDIA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 255 INDIA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 256 INDIA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Government initiatives to support adoption of point-of-care testing
TABLE 257 AUSTRALIA: POINT OF CARE DIAGNOSTICS INDUSTRY, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 258 AUSTRALIA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 AUSTRALIA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 260 AUSTRALIA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 261 AUSTRALIA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Increased funding and product development to propel market growth
TABLE 262 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 263 SOUTH KOREA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 264 SOUTH KOREA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 265 SOUTH KOREA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 266 SOUTH KOREA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 267 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 268 REST OF ASIA PACIFIC: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 REST OF ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 270 REST OF ASIA PACIFIC: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 271 REST OF ASIA PACIFIC: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
TABLE 272 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 273 LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 274 LATIN AMERICA: POINT-OF-CARE AND aDIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 275 LATIN AMERICA: POINT OF CARE DIAGNOSTICS INDUSTRY FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 276 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 277 LATIN AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 LATIN AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 LATIN AMERICA: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 280 LATIN AMERICA: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 281 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 282 LATIN AMERICA: MARKET, BY SAMPLE, 2020–2027 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Rising prevalence of diabetes to support market growth
TABLE 283 BRAZIL: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 284 BRAZIL: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 285 BRAZIL: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 286 BRAZIL: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 287 BRAZIL: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Rising prevalence of diabetes and cancer to drive market
TABLE 288 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 289 MEXICO: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 MEXICO: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 291 MEXICO: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 292 MEXICO: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 293 REST OF LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 294 REST OF LATIN AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 295 REST OF LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 296 REST OF LATIN AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 297 REST OF LATIN AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING PREVALENCE OF HIV TO DRIVE MARKET
TABLE 298 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 299 MIDDLE EAST & AFRICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 MIDDLE EAST & AFRICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 301 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 302 MIDDLE EAST & AFRICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 303 MIDDLE EAST & AFRICA: MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 304 MIDDLE EAST & AFRICA: MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 305 MIDDLE EAST & AFRICA: MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 306 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 307 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS INDUSTRY, BY SAMPLE, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 289)
12.1 INTRODUCTION
TABLE 308 OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019−2022)
12.2 REVENUE SHARE ANALYSIS
FIGURE 34 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
12.3 MARKET SHARE ANALYSIS
FIGURE 35 MARKET SHARE, BY KEY PLAYER, 2021
12.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021)
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
FIGURE 36 MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
12.5 COMPETITIVE LEADERSHIP MAPPING: STARTUP/SME EVALUATION QUADRANT (2021)
12.5.1 PROGRESSIVE COMPANIES
12.5.2 RESPONSIVE COMPANIES
12.5.3 DYNAMIC COMPANIES
12.5.4 STARTING BLOCKS
FIGURE 37 MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS) (2021)
12.6 COMPETITIVE BENCHMARKING
12.6.1 FOOTPRINT ANALYSIS OF COMPANIES
TABLE 309 OVERALL FOOTPRINT OF COMPANIES
TABLE 310 PRODUCT FOOTPRINT OF COMPANIES
TABLE 311 REGIONAL FOOTPRINT OF COMPANIES
12.7 COMPETITIVE SCENARIO
12.7.1 PRODUCT LAUNCHES AND APPROVALS
TABLE 312 POINT OF CARE DIAGNOSTICS MARKET: KEY PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–OCTOBER 2022)
12.7.2 DEALS
TABLE 313 MARKET: KEY DEALS (JANUARY 2019–OCTOBER 2022)
12.7.3 OTHER DEVELOPMENTS
TABLE 314 GLOBAL MARKET: OTHER KEY DEVELOPMENTS (JANUARY 2019–OCTOBER 2022)
13 COMPANY PROFILES (Page No. - 304)
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View)*
13.1.1 ABBOTT LABORATORIES
TABLE 315 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.2 SIEMENS HEALTHINEERS AG
TABLE 316 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
13.1.3 F. HOFFMANN-LA ROCHE LTD.
TABLE 317 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
13.1.4 QUIDEL CORPORATION
TABLE 318 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 41 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
13.1.5 DANAHER CORPORATION
TABLE 319 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
13.1.6 BECTON, DICKINSON AND COMPANY
TABLE 320 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.7 THERMO FISHER SCIENTIFIC
TABLE 321 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
13.1.8 BIOMÉRIEUX S.A.
TABLE 322 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW
FIGURE 45 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2021)
13.1.9 CHEMBIO DIAGNOSTICS, INC.
TABLE 323 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW
FIGURE 46 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2021)
13.1.10 EKF DIAGNOSTICS
TABLE 324 EKF DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 47 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2021)
13.1.11 TRINITY BIOTECH PLC
TABLE 325 TRINITY BIOTECH PLC: BUSINESS OVERVIEW
FIGURE 48 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2021)
13.1.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
TABLE 326 INSTRUMENTATION LABORATORY: BUSINESS OVERVIEW
13.1.13 NOVA BIOMEDICAL
TABLE 327 NOVA BIOMEDICAL: BUSINESS OVERVIEW
13.1.14 PTS DIAGNOSTICS
TABLE 328 PTS DIAGNOSTICS: BUSINESS OVERVIEW
13.1.15 SEKISUI DIAGNOSTICS
TABLE 329 SEKISUI DIAGNOSTICS: BUSINESS OVERVIEW
13.1.16 EUROLYSER DIAGNOSTICA GMBH
TABLE 330 EUROLYSER DIAGNOSTICA GMBH: BUSINESS OVERVIEW
13.1.17 RESPONSE BIOMEDICAL
TABLE 331 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW
13.1.18 ALFA SCIENTIFIC DESIGNS, INC.
TABLE 332 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW
13.1.19 BODITECH MED INC.
TABLE 333 BODITECH MED INC.: BUSINESS OVERVIEW
13.1.20 BTNX INC.
TABLE 334 BTNX INC.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 LIFESCAN IP HOLDINGS, LLC
13.2.2 ASCENSIA DIABETES CARE
13.2.3 FLUXERGY
13.2.4 PRECISION BIOSENSOR, INC.
13.2.5 ACON LABORATORIES, INC.
13.2.6 A. MENARINI DIAGNOSTICS S.R.L.
13.2.7 ORASURE TECHNOLOGIES, INC.
13.2.8 MANKIND PHARMA
13.2.9 TERUMO CORPORATION
13.2.10 GRIFOLS, S.A.
13.2.11 DIASORIN S.P.A.
13.2.12 ACCUBIOTECH CO., LTD.
13.2.13 MERIDIAN BIOSCIENCE
13.2.14 BIOCARTIS
13.2.15 GENESTAT MOLECULAR DIAGNOSTICS, LLC.
14 APPENDIX (Page No. - 390)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the point of care diagnostics market. Extensive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
Secondary Research
The secondary sources referred to in this research study include corporate filings (such as annual reports, SEC filings, investor presentations, and financial statements); research journals; press releases; and trade, business, and professional associations. Secondary sources were used to identify and collect useful information for this extensive and commercial study of the point of care diagnostics market. Secondary research was mainly used to obtain key information about the industry's total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, market trends, and critical developments by both the public and private organisations in the point of care diagnostics market.
The secondary sources referred to for this research study include government sources, independent or public sources, paid or private databases, and research databases, among others. Secondary data was collected and analysed to arrive at the overall market size of the point of care diagnostics market, which was further validated by primary research. Some of the key secondary sources consulted during the preparation of this report are listed below:
- Governmental and intergovernmental sources and databases such as the World Health Organization (WHO), World Bank, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), and National Health Service (NHS), among others
- Business and Research Articles: Springer Nature, The Lancet, PubMed, and the US National Library of Medicine, among others
- Company sources include annual reports, SEC filings, regulatory filings, investor presentations, press releases, and financial statements, among others.
Primary Research
Extensive primary research was conducted after acquiring knowledge about the point of care diagnostics market scenario. A significant number of primary interviews were conducted from the demand (such as hospital labs, reference labs, academic institutes, and point of care testing centers) and supply sides (such as product manufacturers, wholesalers, channel partners, and distributors). The primary respondents interviewed for this study include experts from the point of care diagnostics testing industry (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering point-of-care and rapid diagnostic testing products worldwide) and administrators and purchase managers of hospitals, general physicians, cardiologists, ambulatory care centers, and healthcare service providers.
Around 65% and 35% of primary interviews were conducted from the supply and demand sides, respectively. To validate the report's contents and fill gaps, a strong primary research methodology was used. Telephonic and e-mail communications were adopted to conduct interviews (questionnaires were designed and sent to primary participants as per their convenience).
The point of care diagnostics market comprises several stakeholders, such as diagnostic laboratories and point of care testing laboratories. The demand side of this market is characterised by the growing incidence of infectious diseases, diabetes, and cardiovascular diseases; a rapidly increasing geriatric population; growing funding from public and private organisations for research on rapid tests; and ongoing research for the development of novel point of care tests. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:
A breakdown of the primary respondents is provided below:
*C-level primaries include CEOs, CFOs, COOs, and VPs.
**Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue; as of 2021, Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 =
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the point-of-care and rapid diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size during the above-mentioned estimation process, the global point-of-care and rapid diagnostics market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using the top-down approach.
Report Objectives
- To define, describe, and forecast the point of care diagnostics market by Product, Platform, Mode of Purchase, Sample, End User, and Region
- To provide detailed information about major factors influencing market growth (key drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and their contributions to the overall point of care diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the market value of various segments and sub-segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players active in the point-of-care and rapid diagnostics market and comprehensively analyze their global revenue shares and core competencies2
- To track and analyze competitive market-specific developments such as product approvals & commercialization, agreements, partnerships, collaborations, acquisitions, and expansions in the point-of-care and rapid diagnostics market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global point of care diagnostics market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Rest of Europe point of care diagnostics market into Belgium, Austria, the Czech Republic, Denmark, Greece, Poland, and Russia, among other
- Further breakdown of the Rest of Asia Pacific point of care diagnostics market into New Zealand, Vietnam, the Philippines, Singapore, Malaysia, Thailand, and Indonesia among other
- Further breakdown of the Latin American point of care diagnostics market into Argentina, Chile, Peru, and Colombia, among other
Generating Response ...
Growth opportunities and latent adjacency in Point of Care Diagnostics Market